跳至主要内容
临床试验/NCT07676565
NCT07676565招募中不适用

Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study

Indiana University7 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2026年3月24日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
7
主要终点
Change in HbA1c by type of therapy

研究概览

简要总结

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults ≥18 years of age
  • Clinical diagnosis of T1D
  • GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
  • Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
  • Willing and able to provide informed consent

排除标准

  • No exclusion criteria other than those not meeting inclusion criteria above

结局指标

主要结局

Change in HbA1c by type of therapy

时间窗: 1 year

Change in HbA1c from baseline to over 1 year by those receiving GLP-1RA and SGLTi

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Viral N. Shah

Professor of Medicine

Indiana University

研究点 (7)

Loading locations...

相似试验

Safety and Efficacy of Adjunct Therapies in Adults... | 临床试验